2021 is a very exciting year for KBI with the biggest injection of fresh blood!
With the breakthrough performance and rapid growth of our research services, we have recently recruited 39 new staff members. Our new family members range from university graduates to highly-experienced professionals at the middle and senior levels. They bring in new dynamics, skills and experiences at all levels of KBI, and truly reflect KBI’s values of diversity, merit-based, gender-balanced and equal opportunity.
Kunming Biomed International (KBI) today announced the appointment of Jiming Ye (MD, PhD) as Chief Scientific Officer. Dr. Ye will join company executive team to lead the company’s internal and external drug discovery programs in collaboration with pharmaceutical, biotech as well as academic communities.
Kunming Biomed International (KBI) has previously developed large cohorts of NASH and liver fibrosis models in nonhuman primates (NHPs) mirroring human patient’s disease pathophysiology, clinical progression, and histopathological stages, including steatosis monkeys (n>800), NASH monkeys (n>500) and liver fibrosis monkeys (n>150).
For the upcoming Liver Meeting® 2018 of American Association for the Study of Liver Diseases (AASLD), KBI will present its accomplishments in the development and validation of non-invasive imaging biomarkers such as PDFF and MRI-ECV as well as circulating biomarkers like TIMP-1 for the assessment of hepatic lesions in our NHP model of Nonalcoholic Steatohepatitis (NASH).
Join KBI and more than 9,500 hepatologists and hepatology health professionals from around the world at the annual AASLD conference to be held at the Moscone North and South Convention Center in San Francisco, California on 9-13 November 2018.
Our poster presentation details are below:
Publication Number: 1767
Session Date and Time: Sunday, November 11, 2018, 8:00 AM
Presentation Type: Poster Presentation
Location: Moscone Center North/South Building, Hall C
Our poster presentation details are below:
Poster Board #: SA-PO102
Session Title: Diabetic Kidney Disease: Basic - III [PO0601-3]
Session Date, Time: October 27, 2018 from 10:00 AM to 12:00 PM
Location: Exhibit Hall, San Diego Convention Center
Kunming Biomed International (KBI) announces the hiring of Kaiming Zhang as Head of Eye Diseases. "We welcome Kaiming joining us to strengthen KBI’s capability in metabolic complications such as diabetic retinopathy and establish eye disease technology platform in non-human primates (NHPs). This appointment demonstrates that KBI will continuously enhance the leading position in preclinical services in metabolic diseases and metabolic complications including heart failure, NASH/liver fibrosis, diabetic nephropathy and diabetic retinopathy". In addition, Kaiming’s leadership in this area will facilitate KBI’s quick expansion into other eye disease related to aging”, said Dr. Bob Zhang, CEO of KBI.
Kunming Biomed International (KBI) announces the hiring of Zhiming Ding, MD, Ph.D, as Chief Scientific Officer. "We welcome Zhiming joining our executive management team to further strengthen company's core competence in translational non-human primate (NHP) models in metabolic, cardiovascular and NASH/fibrosis spaces. Appointment of Dr. Ding reflects KBI's continuous commitment and dedication to providing high quality and science-based preclinical services, ultimately translating preclinical potential into clinical success to our collaborators", said Dr. Bob Zhang, CEO of KBI.
Dr. Zhiming Ding brings to KBI over 30 years' experience in biomedical field including 17 years in drug discovery. He has strong expertise in cardiovascular and metabolic diseases and extensive experience in project management and execution. He is the former Research Director and Head of in vivo pharmacology at Lilly China Research Center. He also served at Lexicon Pharmaceutical in the US as the Director of Cardiology/Metabolism. Dr. Ding received his MD and PhD in Toxicology from Tongji Medical University. He had his postdoctoral training at University of Texas at Austin and did research fellow at M.D. Anderson Cancer Center and Baylor College of Medicine.
Kunming Biomed International (KBI) announces the hiring of Noel Miranda, DVM, as Chief Veterinarian. "The appointment of Dr. Miranda demonstrates KBI's commitment to striving the utmost care and highest animal welfare standard. By recruitment of the Chief Veterinarian, KBI’s animal use and care program will be greatly strengthened ", says Dr. Bob Zhang, CEO of KBI.
Dr. Noel Miranda brings to KBI over 30 years’ experience with various species of laboratory animals. He is a pioneering staff at a Japanese NHP Quality Control Facility and GLP-compliant CRO in the Philippines where he supported in its AAALAC accreditation. He is the founding President of the Philippine Association for Laboratory Animal Science (PALAS), and the first author of the Philippine Code of Practice for the Care and Use of Laboratory Animals. He obtained laboratory animal certifications from Japan and is currently advisor of the World Veterinary Association. He has a MSc in Laboratory Animal Science, Royal Veterinary College, University of London.
In KBI, Dr. Noel Miranda will direct the operations of its nonhuman primate (NHP) veterinary care program, personnel, and facilities; paly the primary role of the Institutional Attending Veterinarian with oversight and direction of all animal facilities; and take the ultimate responsibility to ensure that KBI’s institutional animal care, welfare, and use program is implemented in a manner that meets the highest international regulatory animal care and use standards and ethical governance.
Kunming Biomed International (KBI) has developed and characterized a large scale of high fat diet (HFD)-induced NHP models of metabolic diseases and liver diseases including steatosis, NASH and fibrosis. More than 1500 male cynomolgus monkeys have been fed with HFD over a period of 1-6 years and majority of them have developed obesity and diabetic phenotypes as well as progressed to metabolic complications including CKD, CVD and metabolic liver diseases. MRI-based liver fat quantification and percutaneous liver biopsy have exposed significant numbers of monkeys that manifested the full spectrum of non-alcoholic fatty liver disease (NAFLD) ranging from steatosis (more than 800 monkeys) to NASH (more than 800 monkeys) and fibrosis (more than 800 monkeys).
KBI will present this work in this year’s The Liver Meeting® 2017 of American Association for the Study of Liver Diseases (AASLD), hold in Washington D.C., USA, October 20 -24, 2017. KBI’s meeting abstract “Development and Characterization of High Fat Diet-induced Non-human Primate Models of Liver Diseases: Steatosis, NASH and Fibrosis” has been honorably appointed as a Presidential Poster of Distinction for presentation at the meeting, ranking to the top 10% of scored poster abstracts by the Scientific Program Committee of AASLD. KBI’s poster will receive special recognition in the poster hall during the presentation day. Welcome to visit our poster during the meeting or search our abstract from the journal of HEPATOLOGY in its October supplement. Our poster presentation details are below:
Publication Number: 1959
Session Date and Time: October 23, 2017 from 8:00am to 5:30pm
Session: Steatohepatitis: Experimental
Location: Hall D, Walter E. Washington Convention Center, Washington D.C. USA
Also, KBI’s poster is also accessible from AASLD meeting’s ePoster. The poster QR is:
On March 24th , 2017, Kunming Biomed International (KBI) received a letter from AAALAC (Association for Assessment and Accreditation of Laboratory Animal Care International) that KBI’s animal care and use program is granted continuously full accreditation following site visit and program review. The AAALAC International Council on Accreditation recognizes KBI’s effort, contribution and participation in providing and maintaining an excellent program of laboratory animal care and use.
The 56th SOT Annual Meeting which was organized by the Society of Toxicology took place at the Baltimore Convention Center in Baltimore, USA March 12 to 16, 2017. The SOT Annual Meeting is the largest meeting of its kind and more than 6,700 attendees from all over the world participated in this year’s meeting. This annual event featured a broad range of scientific sessions and a thematic program that provided participants with a unique opportunity to deepen the knowledge in specialized topics in toxicology and interact with world leading institutions and companies in their respective disciplines. KBI participated in the meeting’s grand ToxExpo program to exhibit our full spectrum of capabilities in non-human primate biomedical research services. Our exhibition booth attracted a significant number of attendees interested in preclinical non-human primate translational research.